Isotretinoin Drugs Market Report 2026

The isotretinoin drugs market size has grown strongly in recent years. It will grow from $1.35 billion in 2025 to $1.42 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to high prevalence of severe and treatment-resistant acne, established clinical efficacy of isotretinoin, limited effectiveness of alternative acne therapies, widespread dermatologist adoption, availability of capsule-based oral formulations.

The isotretinoin drugs market size is expected to see steady growth in the next few years. It will grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to rising incidence of adult acne, increasing access to dermatology care, growing demand for effective long-term acne solutions, expansion of generic drug manufacturing, improved patient monitoring and safety compliance programs. Major trends in the forecast period include continued use of isotretinoin as a gold-standard therapy for severe acne, growing emphasis on risk management and controlled prescription programs, increasing availability of generic isotretinoin formulations, rising awareness of long-term acne management among adolescents and adults, expansion of isotretinoin use in rare dermatological and oncological indications.

The increasing incidence of skin cancer is expected to drive the growth of the isotretinoin drugs market in the coming years. Skin cancer is characterized by the uncontrolled growth of abnormal skin cells, most commonly resulting from prolonged exposure to ultraviolet (UV) radiation from the sun or tanning beds. The rise in skin cancer cases is mainly attributed to greater UV exposure, ozone layer depletion, and lifestyle changes that involve more outdoor activities without sufficient sun protection. Isotretinoin drugs are used in the prevention and treatment of certain skin cancers because of their ability to limit the proliferation of abnormal skin cells. For example, in January 2024, according to the American Cancer Society, a US-based non-profit organization focused on cancer prevention and control, there were an estimated 108,270 reported cases of skin cancer, representing a 3.2% increase compared with 104,930 cases in 2023. Therefore, the growing number of skin cancer cases is fueling the expansion of the isotretinoin drugs market.

Major companies operating in the isotretinoin drugs market are concentrating on formulation advancements, such as isotretinoin capsules, to broaden treatment options and improve patient access. Isotretinoin capsules are prescribed for severe forms of acne, including nodular or cystic acne, and are used under strict guidelines due to notable side effects, particularly the high risk of birth defects. For instance, in July 2023, Upsher-Smith Laboratories, LLC, a US-based pharmaceutical company, launched its Isotretinoin Capsules USP in strengths of 10 mg, 20 mg, 30 mg, and 40 mg. These capsules are therapeutically equivalent (TE code AB1) to the branded drug Accutane and are indicated for the treatment of severe acne, offering an effective option for challenging cases.

In January 2024, CHEPLAPHARM Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired Roaccutane from F. Hoffmann-La Roche Ltd. for an undisclosed amount. This acquisition enhances the CHEPLAPHARM Group’s dermatology portfolio by securing global rights to Roaccutane and enabling continued worldwide availability of this established retinoid therapy for severe acne. F. Hoffmann-La Roche Ltd. is a Switzerland-based healthcare company involved in the manufacture of isotretinoin drugs, including Roaccutane.

Major companies operating in the isotretinoin drugs market are F. Hoffmann-La Roche Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Hetero Drugs Ltd., Sun Pharmaceuticals Industries Limited, Intas Pharmaceuticals Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals Inc, Zydus Lifesciences Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd, Alembic Pharmaceuticals Ltd, Ajanta Pharma Ltd, Strides Pharma Science Limited, Wockhardt Ltd., Douglas Pharmaceuticals Limited, Chongqing Huapont Pharm Co. Ltd., Cipher Pharmaceuticals Inc.

North America was the largest region in the isotretinoin drugs market in 2025. The regions covered in the isotretinoin drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the isotretinoin drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the isotretinoin drugs market by increasing the cost of imported active pharmaceutical ingredients, intermediates, and specialized excipients used in capsule formulations. These effects have been most noticeable in branded isotretinoin products across North America and Europe, where api sourcing is globally diversified. Asia-Pacific manufacturers have faced pricing pressure due to trade dependencies. However, tariffs have encouraged domestic api production and local manufacturing of generic isotretinoin drugs, supporting supply continuity and cost competitiveness.

The isotretinoin drugs market research report is one of a series of new reports that provides isotretinoin drugs market statistics, including isotretinoin drugs industry global market size, regional shares, competitors with a isotretinoin drugs market share, detailed isotretinoin drugs market segments, market trends and opportunities, and any further data you may need to thrive in the isotretinoin drugs industry. This isotretinoin drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Isotretinoin is a powerful medication derived from vitamin A that is mainly used to treat severe acne, often leading to marked improvement in skin conditions. It works by decreasing oil production and promoting skin cell turnover, resulting in clearer and healthier skin for many patients. It is typically prescribed when other treatments have been ineffective and is used under strict medical supervision with careful evaluation of potential risks and benefits.

The primary types of isotretinoin drugs include capsules and injections. Isotretinoin capsules are oral formulations that reduce the skin’s natural oil production, prevent pore blockage, and help treat and prevent acne. These drugs are indicated for conditions such as severe acne, neuroblastoma, cutaneous T-cell lymphoma, harlequin ichthyosis, xeroderma pigmentosum, fibrodysplasia ossificans progressiva, squamous cell skin cancers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The isotretinoin drugs market consists of sales of softgels, tablets, and ointments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.